Eyenovia Inc is a biotechnology company focused on developing innovative ophthalmic therapeutics utilizing its proprietary delivery technology
The company aims to enhance the treatment of various eye conditions through its advanced product pipeline, which includes specialty pharmaceutical formulations designed to improve the efficacy and patient compliance of eye care treatments. Eyenovia’s pioneering approach leverages microdosing technology to deliver medications more precisely and effectively, potentially transforming the landscape of ocular therapeutics and improving outcomes for patients with vision-related ailments.
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare products, and Eyenovia, Inc. (NASDAQEYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, have commenced activities under a previously announced co-promotion agreement.
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Eyenovia, Inc. (Nasdaq: EYEN) concerning the Company and its directors’ and officers’ possible violations of state laws.
Eyenovia is stepping up the capabilities of its facilities and taking advantage of the thriving innovation culture and expertise in Reno, Nevada, and Redwood City, California
Shares of Eyenovia, Inc. (NASDAQEYEN) traded at a new 52-week high today and are currently trading at $3.78. So far today, approximately 250.22k shares have been exchanged, as compared to an average 30-day volume of 152.26k shares.
San Diego, CA -- (SBWIRE) -- 05/24/2023 -- An investigation was announced for investors of Eyenovia, Inc. (NASDAQEYEN) shares over potential securities laws violations by Eyenovia, Inc.
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Eyenovia, Inc. (Nasdaq: EYEN) concerning the Company and its directors’ and officers’ possible violations of state laws.
In the Digital Health and Startups category at the 2023 Consumer Electronics Show (CES), Eyenovia showcased its Microdose Array Print (MAP™) Technology, the first significant advancement in ocular drug delivery methods in over a century.
The Microdose Array Print (MAP) Technology has shown potential in clinical trials, providing the possibility of more accurate ocular drug delivery than traditional eye droppers
While traditional eye drop bottles require hand-eye coordination and deliver four to five times more medication than the human eye can hold, the Optejet® dispenser's human-centric design administers an easier, more accurate and appropriate dose directly where it is needed in the eye.
Eyenovia, Inc. (NASDAQEYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Eyenovia will be featured at the Company Showcase on July 22 at the Eyecelerator@ASCRS and will participate in a panel discussion, entitled, “Presbyopia: Everybody gets it... but can it be fixed?”
